SecBot SecBot
COURT-RULING ·Filed Feb 27, 2026

ZTS

Zoetis Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago CourtCourt Ruling · courtlistener.com
Court ruling (district)
Actionable Insight ▼ Bearish

The denial of Zoetis' motion increases legal risk and potential liability exposure; traders should monitor for upcoming summary judgment motions or settlement discussions, which may trigger stock volatility. Although the patent has expired, past damages could still be significant given the commercial scale of affected products.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$127.51
T+0 close · Mar 2, 2026 · via day close
Latest settled
−38.10%
T+60 · $78.93
Vs SPY
−47.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $127.51entry
  2. T+1 · 9mo ago −2.35%α −1.47% · $124.52
  3. T+5 · 8mo ago −5.12%α −3.94% · $120.99
  4. T+20 · 8mo ago −9.79%α −2.12% · $115.02
  5. T+60 · 6mo ago −38.10%α −47.73% · $78.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

A U.S. District Court in New Jersey denied Zoetis Inc.'s (ZTS) motion to amend its invalidity contentions in a patent infringement lawsuit brought by Epitopix LLC over SRP2 vaccine technology. The court ruled that Zoetis failed to act diligently in asserting new indefiniteness arguments nearly 20 months after its initial contentions, blocking the addition of last-minute defenses.

Court Ruling Details

Ruling Date
Feb 27, 2026
Court
District Court, D. New Jersey
Court Level
District
Judge
Jessica S. Allen
Case Type
patent
Ruling Type
motion to dismiss
Outcome
LOSS: ruling against this company
Appeal Timeline
30-60 days
Precedent Risk
LOW

Key Facts

  • Zoetis Inc. (ZTS) lost its motion to amend invalidity contentions in a patent infringement case involving U.S. Patent No. 8,637,048 covering SRP2 vaccine technology.
  • The court denied Zoetis' attempt to introduce new indefiniteness arguments under 35 U.S.C. § 112, ruling the motion untimely and lacking good cause.
  • The claims at issue in the litigation are Claims 21, 22, 47, and 50 of the '048 patent, which expired in January 2022 but may still support damages for past infringement.
  • The court emphasized that Zoetis had access to the patent for years and could have raised these grammatical-based indefiniteness arguments earlier, calling the late attempt a litigation strategy, not diligence.
  • This ruling strengthens Epitopix’s position by limiting Zoetis’ ability to challenge patent validity, increasing the likelihood of liability or a favorable settlement for the plaintiff.

Financial Impact

Exposure for past infringement of a vaccine technology used in cattle products like Enviracor J-5; damages magnitude uncertain but potentially material given Zoetis' animal health business scale.

liabilitylegal exposuresettlement risk

Risk Factors

  • Increased likelihood of adverse judgment or forced settlement due to weakened defense position
  • Potential for material damages award if plaintiff proves past infringement of core cattle vaccine products

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 court opinion.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-2b549whu-ZTS

Track record

10 reports on ZTS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +14.79% at T+5 after the May 7, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $82.11 to $79.40 Now $84.39 −2.78% ▲ +3.30% +3.61% vs SPY
  2. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $79.52 to $79.96 Now $84.39 +6.13% ▲ +0.55% +0.22% vs SPY
  3. Oct 13, 20264w ago 8-K Neutral 2/10 Entry $74.30 to $75.29 Now $84.39 +13.58% ▲ +1.33% +2.41% vs SPY
  4. Oct 8, 20265w ago 8-K Neutral 2/10 Entry $74.81 to $75.65 Now $84.39 +12.81% ▲ +1.12% +1.18% vs SPY
  5. Aug 6, 202614w ago 8-K Bearish 7/10 Entry $77.05 to $72.36 Now $84.39 −9.53% ▲ +6.09% +6.70% vs SPY
  6. May 20, 202625w ago 8-K Neutral 2/10 Entry $79.98 to $81.17 Now $84.39 +5.52% ▲ +1.49% +1.04% vs SPY
  7. May 13, 202626w ago Insider Cluster Neutral 2/10 Entry $75.24 to $73.62 Now $84.39 +12.16% ▼ −2.15% −0.93% vs SPY
  8. May 7, 202627w ago 8-K Bearish 7/10 Entry $87.24 to $82.31 Now $84.39 +3.27% ▲ +5.65% +6.48% vs SPY
  9. Apr 8, 202631w ago DEFA14A Neutral 2/10 Entry $119.65 to $119.47 Now $84.39 −29.47% ▼ −0.15% −0.72% vs SPY
  10. Feb 27, 202637w ago Court Ruling Bearish 6/10 Viewing Entry $127.51 to $124.52 Now $84.39 +33.82% ▲ +2.35% +1.47% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 7h 8m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
⚖ Court Ruling · courtlistener.com Report published Apr 21, 2026